Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1249 - Phase 2 study of triplet chemotherapy with oxaliplatin, irinotecan and S-1 (OIS) as first-line treatment in patients with advanced biliary tract cancer (BTC)


09 Sep 2017


Poster display session


Changhoon Yoo


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


C. Yoo1, B. Han2, K. Kim1, H.S. Kim2, J.H. Kim3, H. Chang1, B. Ryoo1, D.Y. Zang2

Author affiliations

  • 1 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 2 Internal Medicine, Hallym University Medical Center, 05505 - Anyang/KR
  • 3 Medical Oncology, Hallym University Medical Center, 07441 - Seoul/KR


Abstract 1249


Although gemcitabine plus cisplatin has been established as the standard first-line chemotherapy for patients with advanced BTC based on the success of the ABC-02 trial, the overall prognosis is still poor as median survival of less than 1 year. Therefore, we investigated novel combination of three drugs including oxaliplatin, irinotecan and S-1, oral fluoropyrimidine, (OIS) for advanced BTC.


Chemotherapy-naïve patients with histologically documented unresectable or metastatic BTC were eligible for this study. Patients received oxaliplatin 65 mg/m2 Day 1, irinotecan 135 mg/m2 Day 1, and S-1 40 mg/m2 BID Day 1-7, every 2 weeks, until the disease progression or intolerable toxicities. Primary endpoint was objective response rate (ORR) defined by RECIST v1.1 and secondary endpoints include progression-free survival (PFS), overall survival (OS) and safety profile. According to the Simon’s optimal two-stage design with type 1 error of 0.05 and a power of 80%, 31 patients were needed with a hypothesis of improving ORR from 20% to 35%.


Between October 2015 and June 2016, a total of 32 patients were enrolled in two referral institutes in Korea. Median age was 64 years (range 40-76) and 24 (75%) patients were male. All but one patient (97%) had metastatic or recurrent disease. Intrahepatic lesion is the most common primary tumor site (n = 13, 41%) and followed by gallbladder (n = 11, 34%) and extrahepatic lesion (n = 8, 25%). With median follow-up duration of 10.1 months, patients received median 12 cycles (range, 1-21) of study treatment. ORR was 50% as partial response was achieved in 16 patients. Median PFS was 7.1 months (95% CI, 5.3-8.8) and median OS was not reached. The 1-year PFS and OS rates were 25% and 59%, respectively. Most common grade 3-4 adverse events were neutropenia (n = 10, 32%), followed by diarrhea (n = 2, 6%) and peripheral neuropathy (n = 2, 6%).


OIS triplet combination chemotherapy was feasible and showed promising efficacy outcomes as first-line treatment in patients with advanced BTC. Randomized trial is needed to validate the efficacy of this triplet regimen.

Clinical trial identification


Legal entity responsible for the study

Hallym University Medical Center and Asan Medical Center




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.